abstract |
The present invention relates to polypeptide-nucleic acid conjugates. These conjugates may allow targeted application of therapeutic RNAi drugs that cross the blood brain barrier, for example, to treat cancer, neurodegenerative diseases, or lysosomal storage diseases. [Selection] Figure 1 |